Bayer said it plans to spend more than $2 billion over the next three years on strengthening and expanding its drug and biologic manufacturing operations.
Medicare announced Thursday that it will limit its coverage of the pricey new drug Aduhelm to Alzheimer's patients enrolled in clinical trials of the drug.
We use cookies only to remember your preferences and provide better browsing experience. We do not sell user information. Here is our privacy policy.